Bajaj Healthcare Share Price

Transcript of Earnings Call for Q2H1FY27

• BSE India
• 6 days 6 hours ago

Intimation for Audio Recording of Earnings Call for Q2FY27

• BSE India
• 2 weeks ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Bajaj Healthcare announced Q2FY27 results</strong></span></h3> <p _ngcontent-ng-c2567179952="" id="financial-highlights-standalone"><strong>Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Revenue from Operations: </strong>Stood at Rs 17,590.16 lakh in Q2FY27, up by 6.20% QoQ compared to Rs 16,563.17 lakh in Q1FY27 and up by 18.92% YoY compared to Rs 14,791.49 lakh in Q2FY26.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Total Income: </strong>Stood at Rs 17,679.40 lakh in Q2FY27, showing a growth of 6.22% QoQ compared to Rs 16,644.31 lakh in Q1FY27 and a growth of 18.20% YoY compared to Rs 14,956.78 lakh in Q2FY26.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Profit Before Tax from Continuing Operations: </strong>Stood at Rs 1,847.59 lakh in Q2FY27, higher by 12.26% QoQ compared to Rs 1,645.83 lakh in Q1FY27 and higher by 15.75% YoY compared to Rs 1,596.21 lakh in Q2FY26.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Net Profit for the Period (Total Operations): </strong>Stood at Rs 1,409.40 lakh in Q2FY27, increasing by 2.89% QoQ compared to Rs 1,369.80 lakh in Q1FY27 and rising by 26.87% YoY compared to Rs 1,110.92 lakh in Q2FY26.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Total Comprehensive Income: </strong>Stood at Rs 1,431.85 lakh in Q2FY27, up by 2.84% QoQ compared to Rs 1,392.25 lakh in Q1FY27 and up by 26.75% YoY compared to Rs 1,129.62 lakh in Q2FY26.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Basic Earnings Per Share (Total Operations): </strong>Stood at Rs 4.19 per share in Q2FY27, up by 2.95% QoQ compared to Rs 4.07 per share in Q1FY27 and up by 18.70% YoY compared to Rs 3.53 per share in Q2FY26.</li> </ul> <p><strong>Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Segment-wise Performance: </strong>The company deals in pharmaceuticals products (formulations and active pharmaceutical ingredient components) which are interlinked and interdependent. Therefore, the company has identified only one reportable segment, i.e., Pharmaceuticals.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Discontinued Operations and Asset Disposals:</strong> <ul> <li _ngcontent-ng-c2567179952="">In Q2FY27, the company sold a portion of its Plot No. D-2/CH/42 & D-2/CH/43 Dahej Industrial Area, GIDC, Bharuch, Gujarat, and subsequently completed the full sale transaction.</li> <li _ngcontent-ng-c2567179952="">In Q1FY27, the Board approved the sale of its unit at Plot No. N-178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar to an unrelated party, classified as Property Held for Sale as of Q2FY27.</li> </ul> </li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Acquisition of Genrx Pharmaceuticals Private Limited: </strong>In Q1FY26, the company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) on a going concern basis for a total consideration of Rs 1,085.00 lakh. In Q3FY27, the company received an order from the Hon'ble NCLT approving the acquisition, following which it will become a wholly owned subsidiary of the company upon fulfillment of procedural conditions.</li> <li _ngcontent-ng-c2567179952=""><strong _ngcontent-ng-c2567179952="">Preferential Issue Proceeds Utilization: </strong>Out of the total Rs 20,497.00 lakh raised via preferential allotment of equity shares and warrants in FY25, the company has utilized Rs 19,905.96 lakh up to Q2FY27 (Rs 15,000.00 lakh for loan repayment, Rs 2,912.48 lakh for capital expenditure, and Rs 1,993.48 lakh for general corporate purposes), leaving an unutilized balance of Rs 591.04 lakh.</li> </ul> <p><strong>Anil Jain, Managing Director, said:</strong> “We have delivered a strong second quarter, with healthy growth across key financial parameters. In fact, our API exports and formulations business combined crossed Rs 100 crore in revenue in Q2FY27. Further, revenue from operations grew 18.9% YoY to Rs 175.9 crore, EBITDA increased 12.2% YoY, with EBITDA margin improving sequentially to 18.2%, and PAT grew 26.9% YoY. For the first half, revenue grew 15.1% and PAT grew 21.1% YoY.</p> <p>As we had expected, formulations rebounded strongly, growing 82% YoY, while API exports grew 28.5% YoY. Further, we have received NCLT approval for acquisition of GenRx which will enable us to further expand our formulation capabilities.</p> <p>The quarter also marked an important milestone in our innovation journey. We became the first company in India to receive DCGI approval for Cenobamate API and Tablets, reinforcing our commitment to building a differentiated specialty portfolio. Our peptide facility remains on track for commissioning in Q4FY27 and the upgrade in our credit rating reflects the stronger balance sheet that we have built.</p> <p>With a strong foundation and clear priorities, we remain committed to delivering sustainable growth and enhancing long - term value for all our shareholders.”</p> <p><a class="lb" href="/get-document/post/pdf/5901576/" target="_blank">Result PDF</a></p>

• Trendlyne
• 2 weeks ago